Fig. 5: Human recombinant chemerin (rh-chemerin) administration improved long-term neurological function and brain morphology at 4 weeks post hypoxic–ischemic encephalopathy (HIE). | Cell Death & Disease

Fig. 5: Human recombinant chemerin (rh-chemerin) administration improved long-term neurological function and brain morphology at 4 weeks post hypoxic–ischemic encephalopathy (HIE).

From: RETRACTED ARTICLE: Chemerin reverses neurological impairments and ameliorates neuronal apoptosis through ChemR23/CAMKK2/AMPK pathway in neonatal hypoxic–ischemic encephalopathy

Fig. 5

a Representative images of Nissl-stained brain sections showing tissue loss in ipsilateral hemisphere at 4 weeks after HIE. Quantification showing rh-chemerin significantly increased the ratio of ipsilateral/ contralateral regions (b) and reduced the percent of tissue loss (c) when compared with vehicle (all samples in Nissl staining were from the same animals which were killed after long-term neurobehavioral tests). d–g rh-chemerin treatment group showed significant improvement in spatial memory in terms of the less swim distance to find the platform (d), less escape latency (e), and more time in the target quadrant (f) when compared with vehicle. Rh-chemerin treatment group significantly improved motor function as demonstrated by foot-fault (h) and rotarod (i) tests; *p < 0.05 compared with sham, #p < 0.05 compared with vehicle, n = 6/group. Data are mean ± SD. Analysis of variance (ANOVA), Tukey

Back to article page